Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration

NCT02307682 is registered in ClinicalTrials.gov with Alcon Research as lead sponsor.

NCT NCT02307682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02307682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
Lead sponsor
Alcon Research
Phase
Phase 3
Overall status
Completed
Start date
December 8, 2014
Completion date
March 28, 2018
Enrollment
1,775 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascularization, neovascular age-related macular degeneration